MiR-497-5p inhibits cell proliferation and metastasis in hepatocellular carcinoma by targeting insulin-like growth factor 1

Guo-shu Xu | Zi-wei Li | Zhi-Ping Huang | F. Charles Brunicardi | Fu Jia | Chao Song | Hai-jian Zou | Rui-fen Sun

1Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, China
2Department of Surgery, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA
3Department of Hepatobiliary Surgery, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China
4Center for Scientific Research, Yunnan University of Chinese Traditional Medicine, Kunming, China
5Department of Orthopedic, National Clinical Key Specialty, Yanan Hospital, Kunming Medical University, Kunming, China

Correspondence
Zhi-ping Huang, Department of Hepatobiliary Surgery, General Hospital of Guangzhou Military Command of PLA, Guangzhou 510000, China.
Email: sola486@163.com

Funding information
National Institutes of Health, Grant/Award Number: NIDDK R01-DK46441 and NCI R01-CA095731; Ann and Jerry Moss Foundation; National Science Fund for Young Scholars, Grant/Award Number: 3150090121; Traditional Chinese Medicine University

Abstract

Background: MicroRNAs (miRNAs) play an important regulatory role in carcinogenesis and cancer progression. Aberrant expression of miR-497-5p has been reported in various human malignancies. However, the role of miR-497-5p in hepatocellular carcinoma (HCC) remains unclear.

Results: In this study, we found that miR-497-5p was downregulated in HCC tissues. The low level of miR-497-5p in HCC tumors was correlated with aggressive clinicopathological characteristics and predicted poor prognosis in HCC patients. The overexpression of miR-497-5p significantly inhibited HCC cell proliferation, colony formation, and metastasis in vitro and in vivo. Bioinformatics analysis further identified insulin-like growth factor 1 (IGF1) as a novel target of miR-497-5p in HCC cells.

Conclusion: Our study suggested that miR-497-5p regulates HCC cell survival, partially through downregulation of IGF1. Therefore, the miR-497-5p/IGF1 axis might serve as a novel therapeutic target in patients with HCC.

Keywords
biomarker, hepatocellular carcinoma, IGF1, miR-497-5p, proliferation

Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBs Ag, hepatitis B surface antigen; HCC, hepatocellular carcinoma; IGF1, insulin-like growth factor 1; IGF1R, insulin-like growth factor 1 receptor; MicroRNAs, miRNAs; OS, overall survival; RFS, recurrence-free survival; TNM, tumor node metastasis; UTR, Untranslated Region.
1 | INTRODUCTION

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide (Bosch, Ribes, Díaz, & Cléries, 2004; Forner, Llovet, & Bruix, 2012; Torre et al., 2015). Despite recent advances in cancer treatment, the majority of HCC patients showed a poor prognosis (Llovet, Fuster, & Bruix, 1999; Ryu, Jang, Kim, Lee, & Chung, 2014). Therefore, understanding the molecular mechanisms of HCC and identifying specific prognostic biomarkers are important for the development of therapeutic strategies for HCC.

MicroRNAs (miRNAs or miRs) are small noncoding RNA molecules of 21–25 nucleotides in length which recognize specific complementary sequences predominantly located in the 3’-untranslated region (UTR) of target mRNAs and function to either repress translation or degrade target mRNAs (Abba, Mudduluru, & Allgayer, 2012; Cho, 2007). miRNAs have been implicated in various forms of cancer by altering the expression of oncogenes or tumor suppressor genes (Abba et al., 2012; Cho, 2007; Fabbri, Calore, Paone, Galli, & Calin, 2013; Hernando, 2007; Nanasinkam & Croce, 2013; Osada & Takahashi, 2007; Setoyama, Ling, Natsugoe, & Calin, 2011). Many miRNAs have been reported to play an important role in HCC (Chen, Li, et al., 2016; Chen, Zhang, et al., 2016; Li, Deng, et al., 2016; Mirzaei et al., 2016; Takata et al., 2016; Yang et al., 2016). However, the characterization of miR-497-5p in HCC and its association with HCC progression remains unclear.

Previous studies have shown that miR-497-5p is of great interest in cancer therapies due to its association with various types of cancer (Chai et al., 2018; Chen et al., 2017; Sun et al., 2017). Here, we found that low miR-497-5p expression in HCC tissues was significantly correlated with poor prognosis of patients; thus, we focused on the roles and corresponding mechanisms of miR-497-5p in the progression of HCC.

2 | MATERIALS AND METHODS

2.1 | Ethical compliance

All the clinical specimens were obtained with informed consent and approved by the Clinical Research Ethics Committee of Yanan Hospital. Informed consent was obtained from all patients involved in this study. All the experiments were performed in accordance with the approved guidelines of the Institutional Research Ethics Committee of Yunnan University of Chinese Traditional Medicine. The data do not contain any information that could identify the patients.

2.2 | Tissue samples

A total of 166 pairs of snap-frozen HCC and peritumoral tissues were obtained from the Yanan Hospital. These tissues were used for quantitative real-time polymerase chain reaction (qRT-PCR) analysis. Clinical tissue samples were verified as tumor or nontumor using a histopathological examination and the Edmondson grading system. Micrometastases were defined as tumors adjacent to the border of the main tumor as observed using a microscope. Tumor staging was defined based on the sixth edition of the Tumor Node Metastasis (TNM) classification system published by the International Union Against Cancer. The tissue samples were stored at −80°C until further use. Tumor differentiation was defined according to the R and Barcelona Clinic Liver Cancer (BCLC) staging systems.

2.3 | Cell culture

Human hepatocellular cancer cell lines (Huh7, HCC-LM3, HepG2, Hep3B, and THLE-3) were purchased from the Shanghai Institute of Life Sciences Cell Resource Center in Shanghai, China. All cell lines were cultured in DMEM medium (Hyclone) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco). All cell cultures were maintained at 37°C in a humidified atmosphere with 5% CO2.

2.4 | Bioinformatics methods

The miRNA targets were predicted using a computer-aided algorithm from TargetScan (http://www.targetscan.org).

2.5 | Quantitative real-time polymerase chain reaction (qRT-PCR)

Mature miR-497-5p expression was detected using a TaqMan miRNA-assay kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. U6 gene was used as a normalization control. All experiments were performed in triplicate and repeated once. To verify the integrity of insulin-like growth factor 1 (IGF1) expression, the GAPDH gene was used as an internal control. PCR was run using the following conditions: 30 cycles consisting of denaturation at 94°C for 30 s, annealing at 56°C (58°C for GAPDH) for 30 s, and extension at 72°C for 30 s. The primer and probe sequences used in the qRT-PCR reactions are listed in Table S2.

2.6 | Western blotting assay

Cell lysates were separated using 10% sodium dodecyl sulfate polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membranes (Roche Diagnostics, Mannheim, Germany), and then detected using anti-IGF1 and anti-IGF1R antibodies. Protein loading was estimated using a mouse anti-GAPDH monoclonal antibody.
Lab Works Image Acquisition and Analysis Software (UVP, Upland, CA, USA) were used to quantify the band intensities.

### 2.7 Luciferase activity assay

The 3’UTR of IGF1 was amplified and cloned downstream of the pGL3/Luciferase (Luc) vector. The mutant 3’UTR of IGF1 (several nucleotides within the binding sites were mutated) was amplified using the pGL3/Luc-IGF1 3’UTR as the template and then was cloned downstream of the pGL3/Luc vector. For the luciferase reporter assay, cells were co-transfected with either miR-497-5p mimics or control and the pGL3/Luc-IGF1 3’UTR or the mutant 3’UTR, together with the controls. At 48 hr after transfection, the cells were lysed using RIPA buffer, and luciferase intensity was measured using an F-4500 Fluorescence Spectrophotometer (HITACHI).

### 2.8 Transfection

For stable transfection, the lentiviral expression vectors LV-Control and LV-IGF1 were obtained from Shanghai Gene Pharma Company (China). Lentiviruses were mixed with polybrene (5 mg/ml) and added Huh7 and HepG2 cells. Positive clones were selected in puromycin (5 mg/ml). Stable IGF1 transfectants were isolated after 2 weeks.

### 2.9 Cell proliferation (MTT) assay and colony formation assay

The transfected cells were plated into 96-well plates at a density of 5,000 cells/well. At 48 hr after transfection, the cells were incubated with MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) for 4 hr at 37°C. The absorbance was measured at 450 nm (OD450nm) using a spectrophotometer. The transfected cells were seeded into 12-well plates at a density of 200 cells/well. The medium was changed every 3 days. Approximately 10 days after seeding, most of the cell clones contained more than 50 cells. The clones were washed with 1 × PBS and stained with Crystal Violet for approximately 5 min. The clones were imaged and counted, and the colony formation rate was calculated using the following formula: (number of clones)/(number of seeded cells) × 100%.

### 2.10 Transwell assays

Milli cell 24-well culture insert plates (Millipore, USA) and polycarbonate membranes with a pore size of 8 μm were used in the transwell assays as follows. First, the insert plates were equilibrated with 0.5 ml of DMEM for 1 hr at 37°C with 5% CO2. The medium was then replaced with 0.5 ml of DMEM supplemented with 10% FBS in the lower chambers. In all, 50,000 cells in 400 μl of serum-free DMEM were loaded into the upper chambers. After 24 hr of incubation, the insert plates were rinsed with PBS, and the upper surfaces of the membranes were scraped to remove the cells. The cells on the underside of the membrane were stained with Giemsa stain and counted using a microscope. The cells from each culture condition were examined in quadruplicate.

### 2.11 Wound healing assays

For the wound healing assays, monolayer of cells plated in 12-well plates were wounded by scraping the monolayer with a 200-μl plastic pipette tip. The cells were then rinsed several times with medium to remove any floating cells. The wound healing process was monitored with an inverted light microscope (Olympus).

### 2.12 IGF1 ELISA

IGF1 levels in normal culture medium collected after 48 hr from different cells were detected with the Human IGF1 ELISA Kit (ab100545; Abcam, CA, USA) according to the manufacturer's instructions.

### 2.13 Animal studies

The animal studies were approved by the Yunnan University of Chinese Traditional Medicine. To explore the effects of miR-497-5p on tumor growth in vivo, 1 × 10⁷ Huh7 cells, which stably overexpressed miR-497-5p, or control cells were subcutaneously implanted into the bilateral armpit of nine BALB/c nude mice. The tumor volume was measured each week following implantation (the volume, V = length × width × length × 1/2). All mice were sacrificed 5 weeks later. Eighteen 6-week-old male nude mice were randomly assigned into two groups; and cells (4 × 10⁵) were injected into the tail vein of the mice to establish a pulmonary metastatic model. The mice were sacrificed 10 weeks after the injection and microscopically examined for the development of lung metastatic foci via H&E staining. The animals were housed in cages under standard pathogen-free conditions, in accordance with the Yunnan University of Chinese Traditional Medicine.

### 2.14 Statistical analysis

All of the data are shown as the mean ± SD, and the experiments were run in triplicate. Statistically significant differences were determined using a two-tailed Student's t-test and p < .05 was considered statistically significant.
3 RESULTS

3.1 miR-497-5p expression is downregulated in human HCC

To explore the role of miR-497-5p in HCC, we first examined the expression of miR-497-5p in HCC cell lines. As shown in Figure 1a, decreased miR-497-5p expression was observed in HCC cell lines compared to normal liver cells. Downregulation of miR-497-5p in HCC cell lines was correlated with the expression observed in HCC tumor tissues. Among 166 matched HCC tumor tissue samples, miR-497-5p was significantly downregulated in tumor tissues compared with the nontumor tissues (Figure 1b). Therefore, we speculated that downregulation of miR-497-5p expression might play an important role in HCC progression and development.

3.2 Decreased miR-497-5p expression predicts aggressive clinicopathological characteristics and poor prognosis in HCC patients

To investigate the clinical significance of miR-497-5p in HCC, the cohort of 166 HCC patients was divided into two groups: a low miR-497-5p expression (below the median expression level, n = 83) group and a high miR-497-5p expression (above the median expression level, n = 83) group. We found that low expression of miR-497-5p was associated with a larger tumor size (≥5 cm) (p = .003), multiple tumors (p = .018) and positive hepatitis B virus (HBV) DNA levels (p = .007) (Table 1). Kaplan-Meier survival analysis showed that the HCC patients in the low miR-497-5p expression group exhibited worse recurrence free survival (RFS) and overall survival (OS) than patients in the high miR-497-5p expression group (p < .001 and p < .001, ***p < .001).
respectively) (Figure 1c,d). The prognosis of some patients with early-stage HCC still turn out to be poor, suggesting that a supplementary prognostic predictor is required for these patients. Therefore, patients with early-stage HCC (TNM stage I) were stratified and subgroup analyses were performed. Notably, the prognosis-predictive value of low miR-497-5p in early-stage HCC (TNM stage I) was still proven (RFS for \( p < .001 \) and OS for \( p < .001 \), respectively) (Figure 1e,f). Similar results were also observed in patients with normal serum AFP level (<20 μg/L) (Figure S1a,b). A univariate analysis indicated that among the clinicopathological characteristics, miR-497-5p expression level, tumor number, vascular invasion, and positivity for AFP or HBV-DNA level were correlated with RFS and OS (Table S1). Furthermore, multivariate Cox regression analysis indicated that miR-497-5p expression level, tumor number, vascular invasion, and positivity for AFP were independent risk factors for RFS, and miR-497-5p expression level and vascular invasion were independent risk factors for OS in HCC patients (Table 2). Taken together, these results indicate that miR-497-5p may represent a valuable prognostic biomarker for HCC.

### 3.3 | Overexpression of miR-497-5p inhibits HCC cell proliferation in vitro and vivo

To determine the effect of miR-497-5p on HCC cell behavior, we stably overexpressed miR-497-5p in the Huh7 and HepG2 cell lines using a lentivirus (Figure 2a). To confirm that miR-497-5p could function as a tumor suppressor, the effects of miR-497-5p overexpression on HCC cell proliferation were determined in vitro. As shown in Figure 2b,c, overexpression of miR-497-5p inhibited HCC cell proliferation. In parallel, Huh7 and HepG2 cells that stably overexpressed miR-497-5p formed fewer colonies compared with the control cells (Figure 2d,e). To determine the effects of miR-497-5p on tumorigenesis in vivo, we injected Huh7 cells that stably overexpressed miR-497-5p or miR-GFP subcutaneously into nude mice for xenograft transplantation. As shown in Figure 2f,g, mice injected with miR-497-5p-overexpressing cells showed significantly decreased tumor growth compared with mice injected with miR-GFP-transfected cells. Therefore, these results indicate that ectopic miR-497-5p expression inhibited HCC cell proliferation in vitro and vivo.

### 3.4 | Overexpression of miR-497-5p inhibits HCC cell metastasis in vitro and vivo

Next, we determined the effects of miR-497-5p overexpression on HCC cell metastasis in vitro. A wound healing migration assay showed that miR-497-5p overexpression could inhibit cell migration in Huh7 and HepG2 cells (Figure 3a,b). Migration and matrigel invasion assays with these

---

**Table 1** Clinical characteristics of the 166 hepatocellular carcinoma patients based on the expression level of miR-497-5p

| Feature                  | miR-497-5p | p-value |
|--------------------------|------------|---------|
| Age, y                   |            |         |
| ≥55                      | 46         | 41      | .437   |
| <55                      | 37         | 42      |        |
| Gender                   |            |         |
| Male                     | 73         | 69      | .377   |
| Female                   | 10         | 14      |        |
| HBsAg                    |            |         |
| Positive                 | 73         | 74      | .094   |
| Negative                 | 10         | 9       |        |
| AFP, μg/L                |            |         |
| ≥20                      | 35         | 36      | .875   |
| <20                      | 48         | 47      |        |
| Tumor size, cm           |            |         |
| ≥5                       | 40         | 59      | .003   |
| <5                       | 43         | 24      |        |
| Tumor number             |            |         |
| Single                   | 57         | 42      | .018   |
| Multiple                 | 26         | 41      |        |
| Vascular invasion        |            |         |
| Absent                   | 71         | 63      | .115   |
| Present                  | 12         | 20      |        |
| Hepatitis B virus DNA, IU/ml |        |         |
| ≥1.0×10^3                | 43         | 51      | .029   |
| <1.0×10^3                | 40         | 23      |        |
| Capsular formation       |            |         |
| Absent                   | 39         | 37      | .283   |
| Present                  | 44         | 46      |        |
| Liver cirrhosis          |            |         |
| Absent                   | 25         | 30      | .410   |
| Present                  | 58         | 53      |        |
| Edmondson-Steiner grade  |            |         |
| I-II                     | 15         | 10      | .278   |
| III-IV                   | 68         | 73      |        |
| BCLC stage               |            |         |
| A                        | 51         | 38      | .043   |
| B+C                      | 32         | 45      |        |
| TNM stage                |            |         |
| I                        | 66         | 41      | <.001  |
| II-III                   | 17         | 42      |        |

*Note:* Abbreviations: AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; TNM, tumor node metastasis.

The median expression level was used as the cutoff value. Low miR-497-5p expression in each of the 83 patients was defined as a value below the 50th percentile. High miR-497-5p expression in each of the 83 patients was defined as a value above the 50th percentile. Pearson’s Chi-square tests were used for the correlation analysis between the expression levels of miR-497-5p and the clinical features. Results were considered statistically significant at \( p < .05 \).
TABLE 2  Multivariate analysis for recurrence free survival and overall survival

| Variable                              | RFS        | OS         |
|---------------------------------------|------------|------------|
|                                       | Hazard ratio | 95% CI     | p-value | Hazard ratio | 95% CI | p-value     |
| AFP, μg/L, ≥20 versus <20             | 1.636      | 1.142 – 2.342 | .007    |             |        |             |
| Microvascular invasion, present versus absent | 1.689      | 1.093 – 2.609 | .018    | 1.758      | 1.118 – 2.763 | .014 |
| Tumor number, multiple versus solitary | 1.834      | 1.227 – 2.740 | .003    |             |        |             |
| miR–497–5p expression, low versus high | 0.274      | 0.180 – 0.418 | <.001   | 0.360      | 0.234 – 0.553 | <.001 |

Abbreviations: AFP, alpha fetoprotein; HBsAg, hepatitis B surface antigen; OS, overall survival; RFS, recurrence free survival.

FIGURE 2  Overexpression of miR–497–5p inhibits hepatocellular carcinoma cell growth in vitro and in vivo. (a) Stable overexpression of miR–497–5p in Huh7 and HepG2 cells, respectively, were established using a lentiviral system and assessed using quantitative real-time polymerase chain reaction. MiR–497–5p expression was normalized to U6 expression. (b, c) MTT assays were performed 24, 48, 72, and 96 hr after transfection to determine the proliferation of Huh7 and HepG2 cells. Data represent the mean ± SD from three independent experiments. (d, e) Colony formation assays were performed in Huh7 and HepG2 cells transfected with miR–497–5p mimics or negative control miR-GFP. The average number of colonies and representative images are shown. (f) Representative images and (g) tumor growth in xenografted mice 5 weeks after subcutaneous injection with either miR–497–5p or miR-GFP cells (n = 9). ***p < .001
miR-497-5p overexpressing cell lines also showed that the exogenous expression of miR-497-5p dramatically decreased cell mobility compared with that of control cells (Figure 3c-f). To verify the in vivo consequences of miR-497-5p overexpression, we injected Huh7 cells that stably overexpressed miR-497-5p or miR-GFP cells into the lateral tail vein of nude mice and evaluated both the metastatic growth in the lungs and the survival of the mice. Ten weeks later, the mouse lungs were stained with H&E and lung micro metastases were microscopically evaluated (Figure 3g, h). Fewer and smaller metastatic foci were detected in the mice injected with the Huh7- miR-497-5p cells than in the control group. In addition, mice injected with Huh7-miR-497-5p cells had a significantly higher survival rate (Figure 3i).

**FIGURE 3** Overexpression of miR-497-5p inhibits hepatocellular carcinoma cell metastasis in vitro and vivo. (a, b) The migratory properties of miR-497-5p-overexpressing cells and control cells were analyzed by scratch wound healing assays in Huh7 and HepG2 cells. Representative results are shown. Magnification: ×100. (c, d) The migratory properties of the cells were analyzed using the Transwell migration assay with Transwell filter chambers. Results are plotted as the average number of migrated cells from six random microscopic fields. (e, f) The invasive properties of the cells were analyzed with the invasion assay using BioCoat Matrigel invasion chambers. Results are plotted as the average number of invasive cells from six random microscopic fields. (g) Representative H&E images of mouse lung tissue sections from the LV-miR-497-5p mimic and LV-Negative control groups (magnification: ×200) black arrows indicated Lung neoplastic foci. (h) The number of metastatic foci in the lungs of each group (n = 9) is presented as the mean ± SD (error bars). (i) Comparisons of the overall survival curves of mice injected with either LV-miR-497-5p mimic or LV-Negative control. p-values were calculated using the two-sided log-rank test. *p < .05; ***p < .001
3.5 | miR-497-5p directly targets IGF1

The miRNA target prediction algorithm TargetScan was used to computationally screen for genes with miR-497-5p complementary sites in their 3’UTR. The results showed that IGF1 was a putative target of miR-497-5p. The miR-497-5p binding sequences in the 3’UTR of IGF1 mRNA (WT-3’UTR) or its mutant (IGF1-3’UTR-mut) reporter plasmids were co-transfected into Huh7 cells with miR-497-5p or miR-GFP. The normalized luciferase activity in the control group was set as the relative luciferase activity. (c) Wild-type (IGF1 3’UTR-WT) or mutant (IGF 3’UTR-mut) reporter plasmids were co-transfected into HepG2 cells with miR-497-5p or miR-GFP. The normalized luciferase activity in the control group was set as the relative luciferase activity. (d) The mRNA expression of IGF1 was analyzed using RT-PCR in Huh7 and HepG2. GAPDH was used as an internal control. (e) The protein expression of IGF1 and IGF1R was analyzed using western blotting in Huh7 and HepG2. GAPDH was used as an internal control. All experiments were performed in triplicate with similar results. (f) The correlation between the miR-497-5p level and IGF1 mRNA level was measured in the same set of tissues. *p < .05; ***p < .001

3.6 | Rescue expression of IGF1 abolished the effects of miR-497-5p on phenotype of HCC cells

To determine if the IGF1 gene is required for the miR-497-5p's effects on HCC cell proliferation and metastasis, ectopic overexpression of IGF1 was performed to conduct functional studies in Huh7 and HepG2 cells (Figure 5a,b). In Figure 5c,d, overexpression of IGF1 abolished the effects of miR-497-5p on inhibiting of HCC cells proliferation. Furthermore, the capacities of migration and invasion in IGF1-overexpression HCC cells were significantly enhanced, while overexpression of IGF1 abolished the effects of miR-497-5p on inhibiting of HCC cells migration and invasion ability (Figure 5e,f). Therefore, overexpressed IGF1 abolished the effects of miR-497-5p on phenotype of HCC cells.
DISCUSSION

Although several studies have demonstrated the signaling pathways involved in the regulation of HCC cell proliferation and cell cycle, the molecular mechanism for HCC cell growth remains unclear (Bosch et al., 2004; Farazi & Depinho, 2006; Forner et al., 2012). MiRNAs offer a novel molecular approach to this question and have been reported to be involved in the pathogenesis of HCC (Toffanin et al., 2011).

In a previous study, miR-497-5p was reported as an oncogene in renal cell carcinoma (Li, Chen, et al., 2016). However, the characterization of miR-497-5p in HCC and its association with disease progression and development remain unclear. In this study, we found that miR-497-5p was downregulated in HCC tumor tissues and HCC cell lines. MiR-497-5p downregulation correlated with a larger tumor size (≥5 cm) (p = .003), multiple tumors (p = .018) and positive HBV DNA levels (p = .007) and predicted poor prognosis. Currently, the HBV DNA levels level is closely related to the recurrence of HCC, and it is used to predict the risk of recurrence in HBsAg-positive HCC patients after hepatectomy. The relationship between the expression of the miR-497-5p and the serum AFP levels suggests that miR-497-5p may be a potential biomarker for diagnosing HCC. Furthermore, its close relationship with the HBV DNA levels and the degree of tumor size also indicates that miR-497-5p may be related to hepatocarcinogenesis. Furthermore, overexpression of miR-497-5p in Huh7 and HepG2 cells significantly inhibited cell proliferation and metastasis both in vitro and in vivo. These results strongly suggest that miR-497-5p has an inhibitory role in HCC.

MicroRNAs can function as tumor suppressors or oncogenes by targeting oncogenes or tumor suppressor genes. In this study, we explored the miR-497-5p targets that may contribute to its inhibition of cell proliferation and metastasis in HCC. Using TargetScan bioinformatics, we identified the IGF1 gene as a possible direct target for miR-497-5p. IGFs are composed of two subtypes, IGF1 and IGF2, and have been shown to regulate the proliferation and differentiation

FIGURE 5 Rescue expression of insulin-like growth factor 1 (IGF1) abolished the effects of miR-497-5p on phenotypes of HCC cells. (a, b) The expression of IGF1 in Huh7 and HepG2 cells, respectively, were examined by quantitative real-time polymerase chain reaction. (c, d) MTT assays were performed 24, 48, 72, and 96 hr after transfection to determine the proliferation of Huh7 and HepG2 cells. Data represent the mean ± SD from three independent experiments. (e, f) The migratory properties of the cells were analyzed using the Transwell migration assay with Transwell filter chambers. Results are plotted as the average number of migrated cells from six random microscopic fields and the invasive properties of the cells were analyzed with the invasion assay using BioCoat Matrigel invasion chambers. Results are plotted as the average number of invasive cells from six random microscopic fields. *p < .05; **p < .01; ***p < .001
of muscle, cartilage, chondrocytes, and neurons (Joung et al., 2013; Kim et al., 2012; Patil, Sable, & Kothari, 2012; Sullivan, Kim, & Feldman, 2012; Wang et al., 2014). IGF1 is secreted primarily from the liver in response to human growth hormone (GH) and acts systemically (Perrini et al., 2010). IGF1 has been shown to play important roles in both normal and pathological biological processes including cancer (Brouwer-Visser & Huang, 2015; Bruchim, Attias, & Werner, 2009; Huat et al., 2014; Livingstone, 2013; Schlegel et al., 2013; Sekharam et al., 2003; Sjögren et al., 2010; Svensson et al., 2007; Tirapegui, 1999; Weroha & Haluska, 2012). Studies have also reported that human IGF1 pro-forms induce breast cancer cell proliferation through the IGF1 receptor. In this study, we performed luciferase reporter assay, real-time PCR, and western blotting to verify that miR-497-5p can directly target IGF1 by interacting with its 3’UTR. The expression level of the IGF1 downstream target gene, IGF1R, was also decreased in miR-497-5p-transfected cells. To the best of our knowledge, our study is the first to report that miR-497-5p acts as a tumor suppressor in HCC. Besides, we observed that miR-497-5p had a negative expression with IGF1 transcription in HCC, and this implies that miR-497-5p might act as a tumor suppressor or have a similar role through decreasing IGF1 expression. Our results indicate that the miR-497-5p/IGF1 axis might serve as a novel therapeutic target in patients with HCC.

In summary, miR-497-5p expression is frequently decreased in HCC tumor tissues and may serve as a prognostic biomarker in patients with HCC. The overexpression of miR-497-5p inhibited HCC cell proliferation by directly suppressing the expression of IGF1, which not only sheds new light on HCC progression and metastasis, but also provides a potential target for cancer prevention and treatment.

ACKNOWLEDGMENTS

The study was funded by the National Institutes of Health grants NIDDK R01-DK46441 and NCI R01-CA095731 and Ann and Jerry Moss Foundation. The study was also funded by the National Science Fund for Young Scholars (3150090121) and by the project of scholar of Traditional Chinese Medicine University.

CONFLICT OF INTEREST

We certify that the authors have no actual or potential conflict of interest in relation to this article.

ORCID

Zhi-Ping Huang https://orcid.org/0000-0001-6045-8513

REFERENCES

Abba, M., Mudduluru, G., & Allgayer, H. (2012). MicroRNAs in cancer: Small molecules, big chances. Anti-Cancer Agents in Medicinal Chemistry, 12(7), 733-743.

Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004). Primary liver cancer: Worldwide incidence and trends. Gastroenterology, 127(5), S5–S16. https://doi.org/10.1053/j.gastro.2004.09.011

Brouwer-Visser, J., & Huang, G. S. (2015). IGF2 signaling and regulation in cancer. Cytokine & Growth Factor Reviews, 26(3), 371–377. https://doi.org/10.1016/j.cytogfr.2015.01.002

Bruchim, I., Attias, Z., & Werner, H. (2009). Targeting the IGF1 axis in cancer proliferation. Expert Opinion on Therapeutic Targets, 13(10), 1179. https://doi.org/10.1517/14728220903201702

Chai, L., Kang, X. J., Sun, Z. Z., Zeng, M. F., Yu, S. R., Ding, Y., … Zhao, J. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells. Cancer Management and Research. 2018;10:989–1003. https://doi.org/10.2147/CMAR.S16335

Chen, J.-S., Li, H.-S., Huang, J.-Q., Dong, S.-H., Huang, Z.-J., Yi, W., … Huang, X.-H. (2016). MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/ACTN signaling in hepatocellular carcinoma. Cancer Letters, 375(1), 73–83. https://doi.org/10.1016/j.canlet.2016.02.043

Chen, W., Zhang, Z., Ding, Z., Liang, H., Song, J., Tan, X., … Chen X. P. (2016). MicroRNA-630 suppresses tumor metastasis through the TGF-β- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget, 7(16), 22674–22686. https://doi.org/10.18632/oncotarget.8047

Chen, X., Shi, C., Wang, C., Liu, W., Chu, Y., Xiang, Z., … Han, X. (2017). The role of miR-497-5p in myofibroblast differentiation of LR-MSCs and pulmonary fibrogenesis. Scientific Reports, 7, 40958. https://doi.org/10.1038/srep40958

Cho, W. C. (2007). OncomiRs: the discovery and progress of microRNAs in cancers. Molecular Cancer, 6(1), 60. https://doi.org/10.1186/1476-4598-6-60.

Fabbri, M., Calore, F., Paone, A., Galli, R., & Calin, G. A. (2013). Epigenetic Regulation of miRNAs in Cancer. Advances in Experimental Medicine and Biology, 754(6), 137–148. https://doi.org/10.1007/978-1-4419-9967-2_6

Farazi, P. A., & Depinho, R. A. (2006). Hepatocellular carcinoma pathogenesis: From genes to environment. Nature Reviews Cancer, 6(9), 674–687. https://doi.org/10.1038/nrc1934

Forner, A., Llovet, J. M., & Bruix, J. (2012). Hepatocellular carcinoma. The Lancet, 379(9822), 1245–1255. https://doi.org/10.1016/S0140-6736(11)61347-0

Hernando, E. (2007). microRNAs and cancer: Role in tumorigenesis, patient classification and therapy. Clinical and Translational Oncology, 9(3), 155–160. https://doi.org/10.1007/s12094-007-0029-0

Huat, T. J., Khan, A. A., Pati, S., Mustafa, Z., Abdullah, J. M., & Jaafar, H. (2014). IGF-1 enhances cell proliferation and survival during early differentiation of mesenchymal stem cells to neural progenitor-like cells. BMC Neuroscience, 15(1), 1–13. https://doi.org/10.1186/1471-2202-15-91

Joung, Y. H., Lim, E. J., Darvin, P., Jang, J. W., Park, K. D., Lee, H. K., … Yang, Y. M. (2013). Hwanggeumchal sorghum extract enhances BMP7 and GH signaling through the activation of Jak2/STAT5B in MC3T3-E1 osteoblastic cells. Molecular Medicine Reports., 8(3), 891–896. https://doi.org/10.3892/mmr.2013.1593
Kim, S., Kang, Y., Krueger, C. A., Sen, M., Holcomb, J. B., Chen, D. I., … Yang, Y. (2012). Sequential delivery of BMP-2 and IGF-1 using a chitosan gel with gelatin microspheres enhances early osteoblastic differentiation. Acta Biomaterialia, 8(5), 1768–1777. https://doi.org/10.1016/j.actbio.2012.01.009

Li, C., Deng, M., Hu, J., Li, X., Chen, L., Ju, Y., … Meng, S. (2016). Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget, 7(13), 17021–17034. https://doi.org/10.18632/oncotarget.7740

Li, Y., Chen, D., Li, Y., Jin, L. U., Liu, J., Su, Z., … Lai, Y. (2016). Identification of miR-130b as an oncogene in renal cell carcinoma. Molecular Medicine Reports, 13(2), 1902. https://doi.org/10.3892/mmr.2015.4744

Livingstone, C. (2013). IGF2 and cancer. Endocrine-Related Cancer, 20(6), R321–R339. https://doi.org/10.1530/ERC-13-0231

Llovet, J. M., Fuster, J., & Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology, 30(6), 1434–1440. https://doi.org/10.1002/hep.5100629

Mirzaei, H., Sahebkar, A., Mohammadi, M., Yari, R., Salehi, H., Jafari, M., … Mirzaei, H. (2016). Circulating microRNAs in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers. Current Pharmaceutical Design, 22(34), 5257–5269. https://doi.org/10.2174/138161282266616033110838

Nanasinkam, S. P., & Croce, C. M. (2013). Clinical applications for microRNAs in cancer. Clinical Pharmacology & Therapeutics, 93(1), 98–104. https://doi.org/10.1038/clpt.2012.192

Osada, H., & Takahashi, T. (2007). MicroRNAs in biological processes and carcinogenesis. Carcinogenesis, 28(1), 2. https://doi.org/10.1093/carcin/bgl185

Patil, A. S., Sable, R. B., & Kothari, R. M. (2012). Role of insulin-like growth factors (IGFs), their receptors and genetic regulation in the chondrocytes and growth of the mandibular condylar cartilage. Journal of Cellular and Developmental Biology: Skeletal Tissues, 5(1), 1796–1804. https://doi.org/10.1002/jcp.22905

Perrini, S., Laviola, L., Carreira, M. C., Cignarella, A., Natalechico, A., & Giorgino, F. (2010). The GH/IGF1 axis and signaling pathways in the muscle and bone: Mechanisms underlying age-related skeletal muscle wasting and osteoporosis. Journal of Endocrinology, 205(3), 201–210. https://doi.org/10.1677/JOE-09-0431

Ryu, S. H., Jang, M. K., Kim, W. J., Lee, D., & Chung, Y. H. (2014). Metastatic tumor antigen in hepatocellular carcinoma: Golden roads toward personalized medicine. Cancer & Metastasis Reviews, 33(4), 965–980. https://doi.org/10.1007/s10555-014-9522-4

Schlegel, W., Raimann, A., Halbauer, D., Schärmer, D., Sagmeister, S., Wessner, B., … Egerbacher, M. (2013). Insulin-like growth factor I (IGF-1) Ec/Mechano Growth factor—a splice variant of IGF-1 within the growth plate. PLoS ONE, 8(10), e76133. https://doi.org/10.1371/journal.pone.0076133

Sekharam, M., Zhao, H., Sun, M., Fang, Q., Zhang, Q., Yuan, Z., et al. (2003). Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Research, 63(22), 7708–7716.

Setoyama, T., Ling, H., Natsugoe, S., & Calin, G. A. (2011). Non-coding RNAs for medical practice in oncology. Keio Journal of Medicine, 60(4), 106. https://doi.org/10.2302/kjm.60.106

Sjögren, K., Sheng, M., Movèrare, S., Liu, J.-L., Wallenius, K., Törnell, J., … Ohlsson, C. (2010). Effects of Liver-Derived Insulin-Like Growth Factor I on Bone Metabolism in Mice. Journal of Bone & Mineral Research, 17(11), 1977–1987. https://doi.org/10.1359/jbmr.2002.17.11.1977

Sullivan, K. A., Kim, B., & Feldman, E. L. (2012). Insulin-like growth factors in the peripheral nervous system. Endocrinology & Metabolism Clinics of North America, 41(2), 375–393. https://doi.org/10.1016/j.ecl.2012.04.020

Sun, Z., Li, A., Yu, Z., Li, X., Guo, X., & Chen, R. (2017). MicroRNA-497-5p Suppresses Tumor Cell Growth of Osteosarcoma by Targeting ADP Ribosylation Factor-Like Protein 2. Cancer Biotherapy and Radiopharmaceuticals, 32(10), 371–378. https://doi.org/10.1089/cbr.2017.2268

Svensson, J., Tivesten, A., Sjögren, K., Isaksson, O., Bergstrom, G., Mohan, S., … Ohlsson, C. (2007). Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression. Journal of Endocrinology, 193(3), 359–366. https://doi.org/10.1677/JOE-07-0024

Takata, A., Otsuka, M., Ohno, M., Kishikawa, T., Yoshihikawa, T., & Koike, K. (2016). Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7. Scientific Reports, 6, 23237. https://doi.org/10.1038/srep23237

Tirapegui, J. (1999). Effect of insulin-like growth factor-1 (IGF-1) on muscle and bone growth in experimental models. International Journal of Food Sciences & Nutrition, 50(4), 231. https://doi.org/10.1080/09637489910110102

Toffanin, F., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., … Llovet, J. M. (2011). MicroRNA-Based Classification of Hepatocellular Carcinoma and Oncogenic Role of miR-517a. Gastroenterology, 140(5), 1618–1628. https://doi.org/10.1053/j.gastro.2011.02.009

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 85–108. https://doi.org/10.3322/caac.21262

Waly Raphael, S., Yangde, Z., Yuixiang, C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncology, 2012:2012(2012). https://doi.org/10.5402/2012/421673

Wang, L. U., Han, Y., Shen, Y., Yan, Z.-Q., Zhang, P., Yao, Q.-P., … Jiang, Z.-L. (2014). Endothelial insulin-like growth factor-1 modulates proliferation and phenotype of smooth muscle cells induced by low shear stress. Annals of Biomedical Engineering, 42(4), 776–786. https://doi.org/10.1007/s10439-013-0957-5

Weroha, S. J., & Halsuka, P. (2012). The insulin-like growth factor system in cancer. Endocrinology & Metabolism Clinics of North America, 41(2), 335–350. https://doi.org/10.1016/j.ecl.2012.04.014

Yang, Y., Liu, W., Ding, R., Xiong, L., Dou, R., Zhang, Y., & Guo, Z. (2016). Comprehensive Expression Profiling and Functional Network Analysis of p53-Regulated MicroRNAs in HepG2 Cells Treated with Doxorubicin. PLoS ONE, 11(2), e0149227. https://doi.org/10.1371/journal.pone.0149227

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Xu G-S, Li Z-W, Huang Z-P, et al. MiR-497-5p inhibits cell proliferation and metastasis in hepatocellular carcinoma by targeting insulin-like growth factor I. Mol Genet Genomic Med. 2019;7:e860. https://doi.org/10.1002/mgg3.860